Trial reportBritish journal of haematology2015
Immune parameter analysis of children with sickle cell disease on hydroxycarbamide or chronic transfusion therapy.
Trial report in British journal of haematology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03111589 (Monocytic Expression of Heme Oxidase-1), which is not on this map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Monocytic Expression of Heme Oxidase-1 (HO-1) in Sickle Cell Patients and Correlation With the Humoral Immune Response to Vaccine and With Allo-immunization
Who cites it
29 citing papers in PubMed.
- Adding hydroxyurea to chronic transfusion therapy for sickle cell anemia reduces transfusion burden.Transfusion · 2025Trial
- Immune Imbalance in Sickle Cell Anemia: Flow Cytometric Insights Into Regulatory T Cells and Neutrophil Dynamics.Journal of clinical laboratory analysis · 2026Article
- Unravelling the Immunological Enigma of Sickle Cell Disease: Current Understanding and Future Directions.Immunology · 2026Review
- Higher aged neutrophils and differential inflammatory profiles in sickle cell disease patients on chronic transfusion therapy versus those on hydroxyurea.Frontiers in immunology · 2025Article
- Unswitched memory B cell deficiency in children with sickle cell disease and response to pneumococcal polysaccharide vaccine.American journal of hematology · 2024Article
- Proinflammatory state promotes red blood cell alloimmunization in pediatric patients with sickle cell disease.Blood advances · 2023Article
- Inhibition of DAGLβ as a therapeutic target for pain in sickle cell disease.Haematologica · 2023Article
- Impact of hydroxyurea on lymphocyte subsets in children with sickle cell anemia.Pediatric research · 2023Article
- Blockade of endothelin-1 receptor B regulates molecules of the major histocompatibility complex in sickle cell disease.Frontiers in immunology · 2023Article
- In-Depth Immunological Typization of Children with Sickle Cell Disease: A Preliminary Insight into Its Plausible Correlation with Clinical Course and Hydroxyurea Therapy.Journal of clinical medicine · 2022Article
- Inflammatory status in pediatric sickle cell disease: Unravelling the role of immune cell subsets.Frontiers in molecular biosciences · 2022Article
- Allogeneic haematopoietic stem cell transplantation resets T- and B-cell compartments in sickle cell disease patients.Clinical & translational immunology · 2022Article
- Article
- Altered type 1 interferon responses in alloimmunized and nonalloimmunized patients with sickle cell disease.EJHaem · 2021Article
- Red blood cell alloimmunization and sickle cell disease: a narrative review on antibody induction.Annals of blood · 2020Article
- Characterization of circulating and cultured Tfh-like cells in sickle cell disease in relation to red blood cell alloimmunization status.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2020Article
- Parvovirus B19 infection in sickle cell disease: An analysis from the Centers for Disease Control haemoglobinopathy blood surveillance project.Transfusion medicine (Oxford, England) · 2020Article
- Polymorphisms in Inflammatory Genes Modulate Clinical Complications in Patients With Sickle Cell Disease.Frontiers in immunology · 2020Article
- Innate immune cells, major protagonists of sickle cell disease pathophysiology.Haematologica · 2020Review
- Characterization of natural killer cells expressing markers associated with maturity and cytotoxicity in children and young adults with sickle cell disease.Pediatric blood & cancer · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Sickle cell disease (SCD) is increasingly appreciated as an inflammatory condition associated with alterations in immune phenotype and function. In this cross-sectional study we performed a multiparameter analysis of 18 immune markers in 114 paediatric SCD patients divided by treatment group [those receiving hydroxycrabamide (HC, previously termed hydroxyurea), chronic transfusion (CT), or no disease-modifying therapy] and 29 age-matched African American healthy controls. We found global elevation of most immune cell counts in SCD patients receiving no disease-modifying therapy at steady state. Despite the decrease in percentage of haemoglobin S associated with CT therapy, the abnormal cellular immune phenotype persisted in patients on CT. In contrast, in both univariate and multivariate analysis, treatment with HC was associated with normalization of the vast majority of leucocyte populations. This study provides additional support for HC treatment in SCD, as it appears that HC decreases the abnormally elevated immune cell counts in patients with SCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.